Interviews

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses ongoing research on biosimilar rituximab, Rixathon.

Kashyap Patel, MD, discusses how biosimilars impact cost in the Medicare Part B context.

Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Denmark has engaged with patients on biosimilars.

Alexandra Valenti, JD, associate at Goodwin, discusses the future of the Biologics Price Competition and Innovation Act (BPCIA) in light of challenges to the Affordable Care Act.

Rolf Benirschke, chief executive officer of Legacy Health Strategies, discusses the challenges patients face in getting access to biologics to treat inflammatory bowel disease.

Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the impact that biosimilars have made on patient access to therapy.

Kashyap Patel, MD, discusses the need for provider education on biosimilars.

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses the benefits that biosimilars have in terms of patient access.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the need for ongoing provider education about biosimilars.

Simon Rule, MD, Plymouth University Medical School, discusses how subcutaneous rituximab has impacted clinical practice.

Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how the NHS has overcome hurdles related to switching to biosimilars.

Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the role of real-world evidence for biosimilar trastuzumab.

Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, addresses whether challenges lie ahead for biosimilars in Denmark.

Suzette Kox, MPharm, secretary general of the International Generic and Biosimilar Medicines Association (IGBA), discusses the need to waive bridging studies in biosimilar development.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilar granulocyte colony-stimulating factor (G-CSF) therapies have impacted cancer care.

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the state of the EU biosimilars market.

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses the rationale for gathering real-world evidence on biosimilar rituximab.

Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses areas where pharmacists still have questions about biosimilars and their implementation.

Elaine Blais, JD, partner at Goodwin and head of the litigation department in Goodwin’s Boston office, discusses whether a recent spate of patent settlements related to biosimilars reflects a shift away from lengthy Biologics Price Competition and Innovation Act (BPCIA) litigation.

Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, discusses patient support options for those who switch to biosimilar adalimumab in the United Kingdom.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilar rituximab may be used in cancer care.

Elaine Blais, JD, partner at Goodwin and head of the litigation department in Goodwin’s Boston office, discusses the Supreme Court’s January 2019 decision in Helsinn v Teva.

Kashyap Patel, MD, discusses the prevailing misconceptions about biosimilars among oncologists.

Simon Rule, MD, Plymouth University Medical School, discusses the role of biosimilar rituximab in the era of subcutaneous reference rituximab in oncology.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses policy challenges with biosimilars.

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses progress made toward the use of global reference products in biosimilar development.

C. Daniel Mullins, PhD, chair of pharmaceutical health services research at the School of Pharmacy, University of Maryland, describes the state of pharmacy school curricula related to biosimilars.

Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Danish patients are benefitting from biosimilars.

Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, reflects on the importance of reporting new cardiac data from the LILAC trial of ABP 980, a trastuzumab biosimilar.

Daniel Mullins, PhD, chair of pharmaceutical health services research at the School of Pharmacy, University of Maryland, discusses how biosimilars are impacting the cost of care.